Cero Therapeutics Files 8-K, Updates Business Address
Ticker: CEROW · Form: 8-K · Filed: Jul 26, 2024 · CIK: 1870404
Sentiment: neutral
Topics: corporate-update, address-change
TL;DR
Cero Therapeutics updated its address. No major news.
AI Summary
On July 26, 2024, Cero Therapeutics Holdings, Inc. filed an 8-K report. The filing indicates a change in the company's business address to 201 Haskins Way, Suite 230, South San Francisco, CA 94080. This is a routine update for the company, formerly known as Phoenix Biotech Acquisition Corp. until June 30, 2021.
Why It Matters
This filing is a standard corporate update, confirming the company's operational location. It does not appear to involve any significant financial transactions or strategic shifts at this time.
Risk Assessment
Risk Level: low — The filing is a routine administrative update and does not contain information that suggests an immediate change in the company's risk profile.
Key Players & Entities
- CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
- 201 Haskins Way, Suite 230, South San Francisco, CA 94080 (location) — New Business Address
- Phoenix Biotech Acquisition Corp. (company) — Former Company Name
- June 30, 2021 (date) — Date of Name Change
- July 26, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a change in the company's business address.
What is the new business address for Cero Therapeutics Holdings, Inc.?
The new business address is 201 Haskins Way, Suite 230, South San Francisco, CA 94080.
When was the company formerly known as Phoenix Biotech Acquisition Corp.?
The company was formerly known as Phoenix Biotech Acquisition Corp. until June 30, 2021.
What is the filing date of this 8-K report?
The filing date of this 8-K report is July 26, 2024.
Does this filing indicate any new financial events or material changes?
Based on the provided text, this filing appears to be a routine update regarding the company's address and does not indicate any new financial events or material changes.
Filing Stats: 566 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2024-07-26 17:20:45
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share CERO NASDAQ Global Market
Filing Documents
- ea021013601-8k_cerothera.htm (8-K) — 26KB
- 0001013762-24-001702.txt ( ) — 241KB
- cero-20240726.xsd (EX-101.SCH) — 4KB
- cero-20240726_def.xml (EX-101.DEF) — 26KB
- cero-20240726_lab.xml (EX-101.LAB) — 36KB
- cero-20240726_pre.xml (EX-101.PRE) — 25KB
- ea021013601-8k_cerothera_htm.xml (XML) — 6KB
01. Other Events
Item 8.01. Other Events. On July 26, 2024, CERo Therapeutics Holdings, Inc., a Delaware corporation (the " Company "), was informed by telephone, subsequently confirmed in writing (the " FDA Communication "), that the Food and Drug Administration (the " FDA ") has placed a clinical hold on the Company's Investigational New Drug Application (" IND ") with respect to its product candidate, CER-1236. The FDA indicated that the clinical hold has been placed as a result of insufficient data provided with regard to two issues within pharmacology and toxicology of CER-1236. The FDA indicated that, within 30 calendar days, it would provide a detailed official hold letter and requested that the Company hold its response until after receipt of such letter (the " Hold Letter "). The Company plans to work expeditiously to resolve this clinical hold so that CER-1236 may proceed to the clinic, including by beginning scientific experimental activities to address the two issues based upon the FDA Communication, as well as earlier discussions with the FDA. Notwithstanding the FDA Communication and pending receipt of the Hold Letter, the Company continues to believe that it will be able to initiate the planned clinical trial by the end of 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 26, 2024 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Brian G. Atwood Name: Brian G. Atwood Title: Chief Executive Officer